The GBM AGILE® (Glioblastoma Adaptive Global Innovative Learning Environment) study is uniquely designed as a long-standing platform with the ability to test multiple therapies at the same time against a common control (or standard of care). The purpose is to evaluate multiple investigational treatments for either newly diagnosed or recurrent glioblastoma to determine if any of these study treatment(s) improve overall survival as compared to standard treatments.

For Patients For Health Care Providers